Cheng, Lei, B.S.
Co-founder & President
- Former Executive Vice President, Hunan Jinsha Pharmaceuticals, China
- Executive Director, Anson Biotech, China
- Member of the Board of Directors in several pharmaceutical companies
- Over 20 years of experience in investment, business development, marketing and commercial transformation deals
Li, Sean (Xiangqun), Ph.D.
Co-founder & Chief Executive Officer
- Former Vice President, Chengdu Shengnuo Biopharmaceutical Co., Ltd., China
- Former Executive Director, WuxiApptec, China
- Former Director, GenScript, China
- Postdoctoral Fellow, University of Maryland, Purdue University, USA
- Postdoctoral Fellow, University of Osaka, Japan
- Ph.D. in Chemistry, Peking University
- More than 25 years of experience in peptide synthetic chemistry and biology, peptide drug and reagent research and production
Gong, Huanzhang, B.S.
Co-founder and Senior Vice President
- Former General Manager, Hunan Jinsha Drug Distribution Co., China
- Investor partner of several pharmaceutical companies
- Over 30 years of experience in marketing, sales and investment in pharmaceutical industry
Liu, Henry Huiqing, M.D.
Senior Vice President
- Former Vice President, PharmaCore Labs, China
- Former Senior Director and Research Fellow, Shanghai Chempartner Co. Ltd., China
- Former Research Scientist/Senior Research Scientist in Neuromed Pharmaceuticals, Canada and Icagen, Inc., USA
- M.D. from Peking University, China
- M.S. in Molecular Biology from University of North Texas and M.S. in Computer Sciences from University of Texas
- More than 25 years of experience in drug screening, bioassays, pharmacology assays, preclinical cardiac safety evaluation, ion channel drugs from early discovery to clinical stages
Yilong, Li, Ph.D.
Director of Medicinal Chemistry
- Ph.D. in Pharmaceutical Science from University of Southern California
- A well-trained pharmaceutical scientist with 5+ years of drug development experience in pharmaceutical industry (GMP Certified Manufacturer), 6+ years in peptide-based drug academia research and 10+ years’ experience in Solid Phase Peptide Synthesis and medicinal chemistry. Dr. Li is also an expert in cyclic peptide-based therapeutics.
- Prior to joining Zosen PepLib, he served as Associate Principal Scientist in Jiangsu Hengrui Medicine Co., Ltd., Senior Scientist in Creative Peptides, and Development Scientist of R&D Department in PolyPeptide Group. During this period, he has led collaboration projects with some big pharmaceutical companies, such as Genentech, Johnson & Johnson, and Bristol-Myers Squibb, etc., of which several projects are in preclinical development, and one project is in phase I clinical trial.
- Dr. Li has published 6 relevant SCI Journals as the first author and has one patent.
Executive Director of the Pharmacology Department
- After trained in Tianjin Medical University, he worked as a clinician for four years. He also received a master's degree in clinical pathology from the University. He got Ph.D. of pharmaceutics at the Department of Pharmacy, Kumamoto University, Japan.
- Dr. Liu has more than 20 years of experience in the pharmaceutical industry, including laboratory research and teaching in drug Discovery (Discovery), Preclinical Drug Research CRO Service (GLP), Clinical Research (GCP) and Big Pharma Pharmaceutical Research Institute (GMP).
- He is currently working as the Executive Director of the Pharmacology Department of Hunan Zonsen PepLib Biotech Co., Ltd., and is mainly responsible for the pharmacological evaluation for new drug development and two new drug development pipelines.
- Prior to joining Zonsen Peplib, he served as the Vice President of Hainan R&D Center in Simcere Pharmaceutical Co., Ltd., the Deputy General Manager of Tiger Fantastic Bioimaging Co., Ltd., and the Senior Director of DMPK of Suzhou Wuxi AppTech Co., Ltd.
- In addition, he was a Research Professor in the Department of Biomedical Engineering at Duke University from 2000 to 2016, where he was engaged in the research and teaching of anti-tumor drug delivery, including research on the delivery of radionuclide drugs, small molecule chemotherapy drugs and glucose-control drugs using thermosensitive elastic protein peptides as carriers, and completed one NIHR01 project and two Duke Cancer Research Center projects.
- Dr. Liu has published 50 SCI Papers and has two patents.
Hong Wang, Ph.D.
Associate Director of Structural Biology
- Ph.D. in Biophysics
- Five-year working experience in the United States as a postdoctoral research fellow in Ruslan Afasizhev's group at Boston University Medical Campus.
- 10+ years of research experience in the filed of structural biology
- Familiar with upstream and downstream processes of structural biology
- Solid experimental skills in molecular and cell biology
- Familiar with bioinformatics data analysis
- Good at crystallization, X-ray and other related structural analysis operations
Sally Wang Liang, Esq., J,D., M.P.H.
VP of Business Development
- Biopharma & healthcare business executive and IP & Regulatory lawyer with 15+ years of healthcare industry experience
- Former FDA Office of Policy and US Senate Health Office
- Former CEO, DocFlight, and CSO, of Click Therapeutics
- Consultant to Pfizer, Sanofi, Novartis, Roche-Genetech, etc.
- J.D. from Harvard Law School, M.P.H from Harvard T.H. Chan School of Public Health, A.B. in Biology with high honors from Harvard College
Rumit Ph.D.
BD Associate Director
- Ph.D. in Chemistry, Arizona State University, USA
- Former Senior Scientist at Merck & Co.
- echnical lead in the technology transfer of PeptiDream Inc.'s peptide drug discovery platform
- More than 7 years of professional research experience in protein engineering, mRNA display platform, peptide chemistry, and cell-free protein expression systems in academia and industry